Frontlight ResearchEarly access
Taking people in SpainPhase 1
Tests drug AP-2 in adults with ALS and related brain disorders
Tests the drug AP-2 in adults with ALS or related brain disorders.
Key facts
- Who runs it
- Molefy Pharma S.L.
- Where
- Madrid, SpainSee the site
- Trial code
- Registry title
- The clinical trial to study a new drug, AP-2.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 64 people, planned
- Started
- 24 Apr 2026
- Expected to end
- 1 Apr 2027
- Type of study
- Interventional
- Record updated
- 27 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 to 64 years. It studies a new drug, AP-2, for ALS and related conditions such as frontotemporal dementia and Alexander disease. Healthy volunteers can also join.
- Age
- 18 to 64 years
- Sex
- Men only
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Spain
- Hospital Universitario de la PrincesaMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests drug AP-2 in adults with ALS and related brain disordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-524480-21-00, who can take part
- Record updated
- 27 October 2026